



Pulmovant, Inc
303 Wyman St, Suite 300
Waltham, MA, 02451, USA

16 April 2026

PHocus Phase 2 RVT-2301-201 Site 2402-Vitulo Recruitment Activity in 2025


Study Title: A Phase 2, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Moslicigat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease

EudraCT Number: 2024-513991-16

The Sponsor, Pulmovant, Inc., of the above-named study hereby declares that the recruitment activity carried out by the IRCCS ISMETT (Istituto Mediterraneo per I Trapianti e Terapie ad Alta Specializzazione), Palermo under the oversight of Principal Investigator Dr. Vitulo, has enrolled in total two (2) participants, all of whom were enrolled in the year 2025.

This declaration is issued at the request of IRCCS ISMETT to comply with the requirements of the Ministry of Health regarding the evaluation of the activities carried out by the IRCCS institution, specifically for the **Reporting of Current Research 2025** (activities carried out in 2025).

Sincerely,

Signed by:
Jennifer Cormier
 Signer Name: Jennifer Cormier
Signing Reason: I approve this document
Signing Time: 4/16/2026 | 11:55:30 AM EDT
3EBEB46C11424F7AA104C9C9EE7857C3

Jennifer Cormier
Chief Development Operations Officer
Pulmovant, Inc.